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Systematic reviewOptimal selection of blood donors is critical for ensuring the safety of blood products. The current selection
process is concerned principally with the safety of the blood donor at the time of donation and of the recipient
at the time of transfusion. Recent evidence suggests that the characteristics of the donor may affect short- and
long-term transfusion outcomes for the transfused recipient. We conducted a systematic review with the
primary objective of assessing the association between blood donor characteristics and red blood cell (RBC)
transfusion outcomes. We searched MEDLINE, EMBASE, and Cochrane Central databases and performedmanual
searches of top transfusion journals for all available prospective and retrospective studies. We described study
characteristics, methodological quality, and risk of bias and provided study-level effect estimates and, when
appropriate, pooled estimates with 95% conﬁdence intervals using the Mantel-Haenszel or inverse variance
approach. The overall quality of the evidencewas graded usingGrading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE)methodology. From6121 citations identiﬁed by our literature search, 59 studies
met our eligibility criteria (50 observational, 9 interventional). We identiﬁed the evaluation of association of 17
donor characteristics on RBC transfusion outcome. The risk of bias and confounding of the included studies was
high. The quality of evidence was graded as very low to low for all 17 donor characteristics. Potential associations
wereobserved fordonor sexwith reducedsurvival at 90daysand6months inmale recipients that receivedonatedblood
from females (hazard ratio 2.60 [1.09, 6.20] andhazard ratio 2.40 [1.10, 5.24], respectively; n=1),HumanLeukocyteAn-
tigen - antigen D Related (HLA-DR) selected transfusions (odds ratio [OR] 0.39 [0.15, 0.99] for the risk of transplant
alloimmunization, n = 9), presence of antileukocyte antibodies (OR 5.84 [1.66, 20.59] for risk of transfusion-related
acute lung injury, n = 4), and donor RBC antigens selection (OR 0.20 [0.08, 0.52] for risk of alloimmunization, n = 4).
Based on poor quality evidence, positive antileukocyte antibodies, female donor to male recipients, HLA-DR selected
RBC transfusion, or donor RBC antigen selectionmay affect RBC transfusion outcome. Our ﬁndings that donor character-
isticsmaybeassociatedwith transfusionoutcomeswarrantestablishingvein-to-veindata infrastructure toallowfor large
robust evaluations. PROSPERO registration number: CRD42013006726.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ContentsResearch Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Material and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
7
7ved for this systematic review.
entist and Director, MHA, PhD, Clinical Epidemiology Program, Box 201B, Ottawa Hospital Research Institute, 501 Smyth Rd,
.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
70 M. Chassé et al. / Transfusion Medicine Reviews 30 (2016) 69–80Search Strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Study Screening and Inclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Inclusion Criteria for Review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Study Type . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Population . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Intervention (Exposure) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Outcomes, Setting, and Timeframe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Exclusion Criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Analysis Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Study Synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Methodological Quality Assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Primary Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Planned Subgroup or Sensitivity Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Quality of Evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Result of the Search . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Study Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Donor Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Donor Age . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Donor Sex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
White Blood Cell Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
RBC Antigen Selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
HLA-DR Selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Other Noninfectious Donor Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Infectious Donor Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Subgroup or Sensitivity Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Risk of Bias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Quality of Evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Competing Interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
71
71
71
71
71
71
71
71
71
71
71
71
71
72
72
72
72
73
73
73
74
74
74
75
76
76
76
76
76
78
78
78
78
78
Appendix A. Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Transfusion of red blood cells (RBCs) is one of the most commonly
used medical interventions in hospital, accounting for more than 108
million yearly units worldwide [1]. The supply of RBCs in North
America relies on voluntary whole blood donation. The quality of RBC
products can be greatly affected by characteristics of these donors
(health status, phenotypes), and an important aim of current measures
in reducing risks for recipients is to better select blood donors. Many
infectious pathogens can be transmitted by blood transfusion and can
lead to recipient contamination potentially affecting their long-term
outcome. Such is the case of human immunodeﬁciency virus (HIV)
and other viruses. These risks can be reduced by a variety of measures,
including donor questionnaires that assess infectious risk, infectious
disease blood screening, and other quality measures already imple-
mented by blood supply agencies [2,3]. For example, better screening
of donors and microbiological testing of the blood products have led
to the reduction of transfusion-related infections [4]. Other characteris-
tics have been suggested to affect outcome of transfusion recipients,
notably in plasma transfusion. For example, female sex, a history of
pregnancy, and the presence of antileukocytes antibodies in blood
products have been associated with the risk of transfusion-related
acute lung injury (TRALI)which is the current leading cause ofmortality
after transfusion [5]. These ﬁndings have led to potentially successful
interventions (transfusion of predominantly male plasma), with a
subsequent decrease in the occurrence of TRALI in Canada [5,6].
Although one could easily draw comparisons between RBC transfu-
sions (“transplanting” blood from a donor to a suitable recipient) and
solid organ or bone marrow transplantation, there is a paucity of data
regarding the impact of donor characteristics on transfusion outcome.
In contrast, the medical literature is extensive regarding the impact of
donor characteristics on outcome of solid organ and bone marrow
transplanted patients [7–11]. Donor characteristics (age, sex, blood
groups, comorbities, etc) are used routinely to determine if a speciﬁcorgan may be suitable for transplantation, to select the best recipient
for a particular organ, and to optimize follow-up of transplanted pa-
tients when some characteristics from the donor are not optimal.
Given the variability in the donor population, such characteristics may
also affect RBC transfusion outcome. Identiﬁcation of donor characteris-
tics associated with transfusion recipient outcomesmay lead to optimal
selection of blood donors and donor-recipient matching. For example,
ﬁndings suggesting that donations from donors with speciﬁc character-
istics negatively affect transfusion outcomes may lead to revised dona-
tion practices with the exclusion of such donors from the donor pool.
We hypothesize that donor characteristics, other than the screening
measures undertaken aiming mostly to reduce the risk of transfusion
transmissible infection, may be associated with RBC transfusion out-
come. To inform transfusion policy and decision making and research,
and in light of the absence of published reviews addressing the clinical
impact of donor characteristics on RBC transfusion recipient outcomes,
we conducted a comprehensive systematic review of the evidence.
Research Objectives
The primary objective of our systematic review is to evaluate the
association of blood donor characteristics (eg, age, sex, RBC antigen)
and the risk of short-term and long-term clinical outcomes of RBC
transfusion recipients. Our secondary objectives are (1) to assess the
methodological quality and the risk of bias of eligible studies and
(2) to identify knowledge gaps and potential future research directions
in the selection of blood donors based on their characteristics.
Material and Methods
We conducted a systematic review of studies evaluating the
association between whole blood donor characteristics and RBC
71M. Chassé et al. / Transfusion Medicine Reviews 30 (2016) 69–80transfusion outcome. The protocol of this systematic review has been
published previously and registered in PROSPERO (www.crd.york.ac.
uk/prospero) CRD42013006726 [12].
Search Strategy
We developed a comprehensive, systematic search strategy with an in-
formation specialist trained in the conduct of systematic reviews. We
searched MEDLINE, EMBASE, and Cochrane Central databases (that include
the Cochrane Database of Systematic Reviews, the Cochrane Central Register
of Controlled Trials, the CochraneMethodology Register, the Database of Ab-
stracts of Reviews of Effects, the Health Technology Assessment Database,
and the NHS Economic Evaluation Database) from inception to December
31, 2013, irrespective of language. We used MeSH (or EMTREE equivalent)
terms in additionwith free-text terms representing the included population,
exposure to blood products and donor characteristics and outcomes, to be
sensitive and inclusive (Appendix 7). At the stage of the literature search,
we applied no restriction on the type of blood product to ensure the most
sensitive search strategy. Reference lists of published narrative reviews,
systematic reviews, and eligible studies were searched for additional refer-
ences up to January 2015.We performedmanual screening of published ar-
ticles since the year 2000 of 5 journals in the ﬁeld of transfusion medicine,
according to the2012ThomsonReuters’ impact factor and fromexpert opin-
ionof themostclinically relevant journals in theﬁeld(Blood,TransfusionMed-
icine Reviews, British Journal of Hematology, Vox Sanguinis, and Transfusion).
Study Screening and Inclusion
We obtained title and abstracts of citations identiﬁed by our search
strategy.Whenan abstractwasnot available, full textwas obtainedunless
the title was clearly irrelevant. All abstracts and titles were screened by 2
independent reviewers using prespeciﬁed inclusion and exclusion
criteria. Full-text copies of relevant reports were then obtained for inde-
pendent analysis by 2 reviewers for ﬁnal inclusion decision. Eligible stud-
ies were then abstracted by 2 independent reviewers using a piloted,
standardized electronic form. Disagreementswere resolved by consensus
and by consultation with a third independent reviewer when needed.
Inclusion Criteria for Review
Study Type
We included observational studies and interventional studies.
Population
The population of interest was patients (in-hospital or outpatient)
with any medical condition requiring at least 1 RBC unit. We included
neonatal, pediatric, and adult patient populations.
Intervention (Exposure)
For this review, we were interested in the impact of whole blood
donor characteristics in relation to transfusion of RBC products. We in-
cluded all studies evaluating at least 1 donor characteristic and its clin-
ical effect on recipients. When a study included recipients of blood
products other than RBCs, the studywas eligible only if we could extract
data regarding the RBC transfusions either from the manuscript or after
contacting the corresponding author. When the intervention was la-
beled as “whole blood transfusion” speciﬁcally, the study was excluded
because these products contain a signiﬁcant proportion of plasma.
Studies reporting “blood products” without any further description
regarding the type of blood products transfused were also excluded
after contacting the corresponding author of the study.Outcomes, Setting, and Timeframe
Our primary outcome was mortality. However, we did not restrict
outcomes in the search strategy or for inclusion. We included any clini-
cal or surrogate outcomes related to donor characteristics.
Exclusion Criteria
We excluded studies in which the study population included
nontransfused patients and from which it was impossible to obtain results
for transfused patients. To be eligible, a study also had to report a measure
of association between a donor characteristic and a transfusion outcome.
We excluded studies reporting expected associations between donor and
recipients (eg, using mathematical modeling). Case series were excluded
unless an interrupted time-series design was used. We excluded case re-
ports (≤2 cases) andduplicates or “subcohorts”of alreadypublished studies.
Analysis Plan
Study Synthesis
For each eligible study, we described the study origin (country, date)
and design characteristics (retrospective, prospective, interventional,
etc). We provided a description of the population studied including the
total number of patients, clinical characteristics, the number of transfused
patients, the blood products transfused with the proportion for each type
of blood product, the characteristics of included patients (age, sex, and
reasons for transfusion), and inclusion and exclusion criteria.
Methodological Quality Assessment
Themethodological quality of the included studies in this systematic re-
viewwasevaluatedby2 independent reviewersusing theDownsandBlack
tool for assessing risk of bias (Appendix 3) [13]. Speciﬁc coding instructions
were provided to the reviewers and were piloted before implementation.
Primary Analysis
For each of the donor characteristics, we abstracted the number of ex-
posed and nonexposed patients with the studied outcome. We also ab-
stracted unadjusted and adjusted odds ratios (ORs), relative risks, risk
ratios (RRs), or hazard ratios (HRs). When appropriate, we provided
pooled effect estimates as pooled log-odds ratios or risk ratios with 95%
conﬁdence intervals (CI) using a random effects modeling approach.
For dichotomous variables, we used the Mantel-Haenszel approach and
computed odds ratios and 95% CIswhen the number of exposed and non-
exposed patients was available. For continuous outcomes or when the
number of exposed and nonexposed patients was not provided, we com-
puted mean differences and 95% CIs using the DerSimonian and Laird
method. Statistical heterogeneity was reported using the I2 test with
95% CIs. To investigate publication bias, the funnel plot techniques was
used. All analyses were performed using RevMan version 5.3 (Copenha-
gen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).
Planned Subgroup or Sensitivity Analysis
To explore clinical and statistical heterogeneity, we planned to re-
port if possible pooled log-odds ratio for the following subgroups:
(1) adults ≥18 years vs mixed children/adults, only children vs only
adults, and we considered subgroups among children (b1 month and
neonates vs other children b18 years); (2) hospitalized patients vs out-
patient transfused patients; (3) patients transfused in an intensive care
unit vs hospitalized but not in an intensive care unit; (4) signiﬁcant
changes in donor inclusion criteria ormanufacture strategy; (5) surgical
vs medical populations (≥75% of included patients); (6) patients
with acute vs chronic anemia; and (7) continent where the studies
were conducted.
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Two reviewers evaluated the quality of the evidence according to 5
domains: study limitations, inconsistency of results, indirectness of
evidence, imprecision, and reporting bias using the GRADE methodology
[14]. We reported the quality as very low, low, moderate, or high.
Results
Result of the Search
Our search strategy identiﬁed 6121 citations of which 6044 citations
were obtained from our electronic search and 77 citations were found by
hand search (Fig 1). Following the screeningof titles andabstracts to exclude
nonrelevant and duplicate studies by 2 reviewers independently, 105 re-
ports remained for full-text screening andabstraction. A further 46 reports
were excluded because the main focus was either whole blood or un-
speciﬁed blood components (Appendix 2 for description of excluded re-
ports), and thus, 59 studies remained for the review (Appendix 1).Records identified  
through original 
database search: n = 
6044
Additional records id
through other sou
n = 77 from referenc
included pape
Number of records after duplicates 
removed, that were screened by 
title/abstract: n = 5702
Number of full texts assessed for 
eligibility: n = 518
Number of studies included in qualitative 
synthesis: n = 105
Nu
Full texts with RBC data: n = 59*
Donor age: n = 5
Donor sex: n = 17
Donor cancer: n = 1
HLA antigen selection: n = 12 
WBC antibody status: n = 7
RBC antigen selection: n = 5 
Previously pregnant or transfused: n = 4 
“Walking donor” program: n = 1
Parental donor: n = 1
Babesiosis: n = 2
Cytomegalovirus: n = 3
Hepatitis B virus: n = 3
Hepatitis C virus: n = 5
Human Herpesvirus-8: n = 1
Human T-lymphotrophic virus: n = 4
Liver biochemistry test status: n = 1 
Human parvovirus B19: n = 1 
Fig 1. PRISMAStudy Characteristics
Overall, 9 studies (n = 5143 patients) were interventional (5 ran-
domized) and 50 were observational (n N 417278, not reported in all
studies). Of the observational studies, 39were retrospective and 11 pro-
spective. Observational designs included time-series (n = 18), cohort
studies (n = 19), look-back (n = 3), trace-back (n = 5), and case-
control (n = 5). All but 6 studies (1 Uganda, 1 Jamaica, 1 Columbia, 1
Kuwait, and 2 Japan) were conducted in North America (n = 26) or
Europe (n = 27). Publication years ranged from 1976 to 2013, with 35
(59.3%) published since 2000. We included 2 studies where the
exact proportion of RBC transfusions was not reported but the au-
thors reported an adjusted analysis by blood component [15,16].
One study reported RBC-related TRALI events without denominator
data [17]. For 24 studies, we were able to extract data for patients
that received RBCs only (ie, no other blood products). Five studies
reported RBC donor-recipient antigen matching strategies, 4 donor
sex, 12 selective HLA-DR matching in transplant populations, and 2
donor age.* A study can be included
in different categories.
entified 
rces:
e lists of
rs
Records excluded after 
title/abstract screening: 
n = 5185
mber of full texts excluded: n = 413
Full text not available: n = 26
Language (unable to translate): n = 1
Study design: n = 90
Population: n = 126
No donor characteristic measured: n = 34
Only non-RBC transfusions (e.g., plasma, 
platelets, cryoprecipitate): n = 16
RBCs transfused, but no RBC data: n = 54
Lack of comparator: n = 52
No outcome measured on recipients: n = 2
Companion paper to an included study: n = 12
Full texts with whole blood or 
unnamed blood component data 
excluded after abstraction: n = 46
ﬂowchart.
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We identiﬁed 17 different donor characteristics studied (Fig 1).
Detailed results of our analyses are presented in Tables 1-5 and in
Appendix 6. We summarized the results by patients either receiving
RBC products only and those receiving RBC and other blood products.
Donor Age
We identiﬁed 5 studies that provided clinical outcome estimates for
donor age (Table 1 and Appendix 6). The outcomes of interests were
mortality (n = 1), TRALI (n = 3), change in human T-lymphotropic
virus (HTLV) infection status (n = 1), and HIV infection (n = 1). All
were retrospective and included a total of 586 recipients.
RBC Transfusions Only. Two studies [18,19] presented data for patients
receiving RBC transfusions only. One study reported the incidence of acute
lung injury [18], whereas the other study reported the rate of immune-
mediated vs non–immune-related TRALI [19]. Both studies reported no sig-
niﬁcant association between donor age and the risk of TRALI (age difference,
−0.18 [−6.67, 6.31] for maximum donor age) or immune-related TRALI
(age difference, 7.0 [−13.64, 27.64] for maximum donor age).
RBC Transfusions and Other Blood Components. In 3 studies reporting
donor age as a potential risk factor for adverse RBC transfusion outcome,
recipients were also transfused other blood products in addition to RBCs
(Table 1) [15,20,21]. From data provided by the author of 1 study [15],
maximum donor age was on average 6.24 years lower in patients who
survived hospitalization (age difference, −6.24 [−12.43, −0.05]).
Despite design limitations (retrospective case-control study) and the
fact that all patients also received plasma transfusion, this study was of
good reporting qualitywith low risk of bias. Two additional studies tested
the association between donor age and HIV [20] or HTLV [21] transmis-
sion. No numerical values were provided by either study, but the associa-
tion was reported as not signiﬁcant. Those studies had poor reporting
quality and were at high risk of bias and confounding (Appendix 5).
Donor Sex
Seventeen studies (1 prospective, 16 retrospective) were eligible for
review for the donor sex characteristic (Table 2). Six studies were time
series studying “before and after” an organizational policy change for
blood donation [17,22–27]. Nine studies were case-control (n =
3) [15,28,29], cohorts (n = 4) [21,30–32], or trace-back studies (n =
2) [19,33]. One study reported both a case-control study and a before-
and-after study [5]. Four studies reported data for RBC transfusions sep-
arately [19,30,32,34]. Two types of donor sex comparisons were avail-
able from the included studies: donor sex alone and donor-recipient
sex mismatch. The reported outcomes were mortality (n = 2), TRALI
(n = 13), change in HTLV infection status (n = 1), mosaicism (n =
1), and the risk of necrotizing enterocolitis (n = 1).Table 1
Estimates of association between donor age and RBC transfusion outcomes
Outcome or subgroup Studies Effect estimate (with 95% CI)
Donor age
Hospital mortality
Mean donor age 1 MD−4.62 [−9.92, 0.64]
Maximum donor age 1 MD−6.24 [−12.43,−0.05]
ALI ≤6 h after transfusion
Mean donor age 2 MD 3.40 [−4.97, 11.78]
Maximum donor age 2 MD 0.47 [−5.73, 6.66]
ALI ≤ 72 h after transfusion 1 OR 1.14 [0.52, 2.49]
ALI 72 h to 28 d after transfusion 1 OR 0.86 [0.38, 1.96]
ALI ≤28 d after transfusion 1 OR 0.98 [0.51, 1.88]
HTLV transmission 1 Multivariate model including dono
54 patients analyzed. Numerical va
HIV transmission 1 Maximum likelihood estimation of
Reported as: "The HIV-1 transmissRBC Transfusions Only. Three studies [19,30,32] reported a measure of
association between donor sex and transfusion outcome and 1 study
for donor-recipient sex mismatch [34]. In a retrospective cohort of 122
patients, Paul and colleagues [32] found that in neonates developing
necrotizing enterocolitis within 48 hours after transfusion, 84% of RBC
units transfused were from male donors compared with 62% in neo-
nates that developed necrotizing enterocolitis greater than 48 hours
after transfusion (P = .03). A study including 10 patients by Porretti
et al [19] did not ﬁnd an association between donor sex and immune-
mediated TRALI. Finally, a study of 10 neonates [30] receiving RBC trans-
fusions found no evidence of karyotype mosaicism according to donor
sex. The risk of bias was high for all studies.
For donor sex mismatch, Middelburg et al [34] found an improved
survival at 90 days and 6 months among male recipients younger than
55 years who received only red cell transfusion from male donors (HR
2.60 [1.09, 6.20] and HR 2.40 [1.10, 5.24], respectively). Statistical
signiﬁcance was no longer observed at 5 years (HR 1.40 [0.94, 2.08]).
There was no such association in female recipients. Reporting quality
was good and the risk of bias low.
RBC Transfusions and Other Blood Components. For donor sex, 7 studies
reported the rate of RBC-related TRALI before and after policy changes
that included implementation of predominantly male plasma donors
and, in some reports, the exclusion of previously alloexposed donors
[5,17,23–27]. In those studies, the interventions were aiming to reduce
exposure of female blood in plasma products, but we extracted RBC-
related TRALI. A meta-analysis of those 7 included reports showed a re-
duced risk of TRALI in favor of the policy change of reduced exposure to
female blood donations (RR 0.50 [0.35, 0.72], I2 0%). Patients included in
those studies also received other blood products in a proportion ranging
between 14.6% and 100% for plasma. Given the design (before-and-after
studies) of those reports [5,17,23–27], the risk of bias and confounding
was high for all included studies. We pooled 4 studies (3 case-control
and 1 trace-back study) directly measuring the risk of TRALI in RBC re-
cipients and found no such association (OR 1.03 [0.64, 1.68], I2 0%)
[5,15,19,28]. One before-and-after study reported cases of RBC-
associated TRALI and the total number of units transfused during the
study period and found no evidence of association [22]. One recipient
trace-back study reported a signiﬁcantly increased risk of TRALI-
related death for recipients of blood from antibody-positive female do-
nors compared withmale donors or antibody-negative donors (RR 9.00
[1.92, 42.24]) [33]. This study was of low reporting quality, included 18
recipients, and was at risk of confounding, and 59% of the blood prod-
ucts transfused were plasma. One study looking at the risk of HTLV
transmission found no association with donor sex [21].
One report estimated the risk of mortality and of acute lung injury
for donor sex mismatch [15]. In this study, for the subgroup of patients
that received RBCs, there was no association between donor sex
mismatch and the risk mortality or acute lung injury (OR 1.04 [0.50,Interpretation
Null, favors older donors
Favors older donor
Null
Null, favors younger donors
Null, favors no donor N63
Null, favors at least 1 donor N63
Null
r age as a risk factor for HTLV-I conversion.
lue not provided. Reported as not signiﬁcant.
Null
HIV transmission adjusted for covariates.
ion rate did not vary by the donor's age…"
Null
Table 2
Estimates of association between donor sex and RBC transfusion outcomes
Outcome or subgroup Studies Effect estimate (with 95% CI) Interpretation
Donor sex
RBC-associated TRALI risk after policy change 7 RR 0.50 [0.35, 0.72], I2 0% Favors after policy change
RBC-associated TRALI from male vs mixed donors 4 OR 1.03 [0.64, 1.68], I2 0% Null
Nonfatal TRALI risk/unit distributed 1 OR 0.87 [0.40, 1.88] Null, favors male donors only
Fatal TRALI risk/unit distributed 1 OR 0.37 [0.07, 1.93] Null, favors male donors only
TRALI-related death vs non–TRALI-related death 1 RR 9.00 [1.92, 42.24] Favors male donors and
antibody-negative
female donors
Transfusion reactions 1 OR 1.06 [0.94, 1.19] Null
TRALI/no. of units
Male donors 1 OR 0.96 [0.73, 1.26] Null
Female donors 1 OR 1.03 [0.75, 1.41] Null
Antibody-mediated TRALI
vs non–antibody-mediated
1 OR 4.20 [0.12, 151.96] Null, favors male donors
Genetic mosaicism 1 Male vs usual donor populations.
Statistical method unclear. Authors report:
"Given the male to female donor ratio in our
blood bank of approximately 1:1, the probability of any
patient being transfused with blood from a donor of opposite sex is 50%.
The observation of no instances of even mosaic discordant karyotypic sex
in any of our 10 patients is highly signiﬁcant, with a likelihood of 0.001."
Null
Necrotizing enterocolitis 1 84% of RBC units were from males in the NEC
within 48 h of transfusion group, 62% of RBC units were
from males in the NEC N48 h group.
Authors report a P value of .03.
Favors female donors
HTLV infection 1 Multivariate model including donor sex as a risk factor for HTLV-I conversion.
54 patients analyzed. Numerical value not provided.
Reported as not signiﬁcant.
Null
Donor sex mismatch
Hospital mortality
Female recipients 1 OR 1.05 [0.22, 5.13] Null
Male recipients 1 OR 0.70 [0.18, 2.75] Null, favors sex mismatch
All recipients 1 OR 1.05 [0.40, 2.73] Null
Survival 1 mo posttransfusion
Female recipients 1 HR 1.10 [0.43, 2.84] Null, favors no sex mismatch
Male recipients 1 HR 2.20 [0.86, 5.64] Null, favors no sex mismatch
All recipients 1 HR 1.40 [0.73, 2.68] Null, favors no sex mismatch
Survival 90 d posttransfusion 1
Female recipients 1 HR 1.50 [0.59, 3.79] Null, favors no sex mismatch
Male recipients 1 HR 2.60 [1.09, 6.20] Favors no sex mismatch
All recipients 1 HR 1.80 [1.00, 3.24] Favors no sex mismatch
Survival 6 mo posttransfusion 1
Female recipients 1 HR 1.20 [0.56, 2.59] Null, favors no sex mismatch
Male recipients 1 HR 2.40 [1.10, 5.24] Favors no sex mismatch
All recipients 1 HR 1.60 [0.96, 2.67] Null, favors no sex mismatch
Survival 5 y posttransfusion 1
Female recipients 1 HR1.20 [0.69, 2.09] Null, favors no sex mismatch
Male recipients 1 HR 1.70 [0.92, 3.14] Null, favors no sex mismatch
All recipients 1 HR 1.40 [0.94, 2.08] Null, favors no sex mismatch
Acute lung injury 1
Female recipients 1 OR 0.78 [0.20, 3.01] Null, favors sex mismatch
Male recipients 1 OR 1.38 [0.35, 5.44] Null, favors no sex mismatch
All recipients 1 OR 1.05 [0.40, 2.73] Null
74 M. Chassé et al. / Transfusion Medicine Reviews 30 (2016) 69–802.73] for mortality, 1.05 [0.40, 2.73] for acute lung injury). All patients
also received plasma. Reporting quality was good and the risk of bias low.
White Blood Cell Antibodies
Seven studies assessed at least 1 donor antibody directed to any type
of white blood cell (WBC) antibodies (Table 3). One study found no
association between donorWBC antibodies andmortality [15]. Four ob-
servational studies suggested an increased risk of TRALI (OR 5.84 [1.66,
20.59], I2 62%) [15,33,35,36]. The risk of bias and the statistical heteroge-
neity for the 4 studies were high. One study measured the risk of TRALI
in relation to the anti-WBC antibodies titers and reported a signiﬁcant
association, favoring low-antibody titers (OR 3.20 [1.52, 6.74]) [5]. All
studies included patients that received RBC and other blood products.
RBC Antigen Selection
Five studies (4 observational, 1 nonrandomized intervention study)
reported the association of donor RBC antigen selection on transfusionoutcome (Table 3) [37–41]. One study found no association between a
donor-recipient cross-match (vs no crossmatch) and the risk of clinical
hemolysis (OR 0.74 [0.03, 15.83]) [38]. Three studies reported the risk of
alloimmunization after transfusion of mismatched vs matched blood
[37,39,40]. Overall, transfusion ofmatched RBC products was associated
with a reduction in the risk of alloimmunization (OR 0.20 [0.08, 0.52], I2
58%). The heterogeneity and risk of bias were high for all studies.
HLA-DR Selection
We identiﬁed 12 studies (2 RCTs, 3 nonrandomized intervention
studies, 5 prospective cohorts, and 2 retrospective cohorts) reporting
the association betweenHLA-DR selection andRBC transfusion outcome
(Table 3). All recipients were transplant candidates (renal in 11 studies
and cardiac in 1 study). All patients received only RBC transfusions.
There was no evidence of association between HLA-DR selection and
mortality (n = 1 study) [42], patient survival (n = 2 studies) [42,43],
graft survival (n = 4 studies) [43–46], and microchimerism (n = 1
Table 3
Estimates of association between donor antibodies or antigen and RBC transfusion outcomes
Outcome or subgroup Studies Effect estimate (with 95% CI) Interpretation
WBC antibody
Mortality 1 OR 0.45 [0.14, 1.48] Null, favors presence of antibody
TRALI 4 OR 5.84 [1.66, 20.59], I2 62% Favors absence of antibody
TRALI—after implementation of a no WBC antibody policy 1 RR 0.64 [0.07, 5.85] Null, favors after policy change
Fatal vs nonfatal TRALI 1 OR 0.71 [0.11, 4.65] Null, favors presence of antibody
Increase of TRALI risk by antigen titer increase 1 OR 3.20 [1.52, 6.74] Favors low antibody titer
RBC antigen selection
Hemolysis 1 OR 0.74 [0.03, 15.83] Null, favors positive cross-match
Alloimmunization 4 OR 0.20 [0.08, 0.52], I2 58% Favors matched blood
HLA-DR antigen selection
Mortality 1 OR 0.45 [0.16, 1.29] Null, favors HLA-DR matched
1-y graft survival 3 OR 1.27 [0.37, 4.36], I2 49% Null, favors HLA-DR mismatched
5-y graft survival 2 OR 1.10 [0.56, 2.18], I2 0% Null, favors HLA-DR mismatched
1-y patient survival posttransplant 2 OR 0.45 [0.10, 2.02], I2 0% Null, favors HLA-DR matched
5-y patient survival posttransplant 2 OR 1.02 [0.11, 9.79], I2 68% Null
Acute renal rejection b 6 mo posttransplant 2 OR 0.36 [0.14, 0.91], I2 0% Favors HLA-DR matched
Acute renal rejection at any time after transplant 1 OR 0.47 [0.16, 1.35] Favors HLA-DR matched
N1 acute renal rejection episode over follow-up 2 OR 0.50 [0.29, 0.88], I2 0% Favors HLA-DR matched
Alloimmunization 9 OR 0.39 [0.15, 0.99], I2 66% Favors HLA-DR matched
Microchimaerism
1-4 d posttransfusion 1 Not estimable Not estimable
5-7 d posttransfusion 1 OR 17.89 [0.76, 420,49] Null, favors HLA-DR mismatched
2-4 wk posttransfusion 1 OR 11.67 [0.92, 147.56] Null, favors HLA-DR mismatched
5-8 wk posttransfusion 1 OR 1.33 [0.10, 17.10] Null
75M. Chassé et al. / Transfusion Medicine Reviews 30 (2016) 69–80study) [47]. Pretransplantation HLA-DR matched transfusion reduced
the rate of renal rejection b6 months after transplantation in 2 studies
(OR 0.50 [0.29, 0.88], I2 0%) [43,48] and at any time after transplantation
in 1 study (OR 0.47 [0.16, 1.35]) [43], and the number of rejection
episodes posttransplant in 2 studies (OR 0.50 [0.29, 0.88], I2 0%)
[42,45]. In 9 studies (1 RCT, 3 nonrandomized intervention trials, and
5 observation studies), the rate of alloimmunization posttransplanta-
tion was reported. The overall risk of alloimmunization was reduced
by the transfusion of HLA-DR matched RBC products (OR 0.39 [0.15,
0.99], I2 66%) [44–46,48–53]. All studies were of different designs and
at high risk of bias and confounding, and the statistical heterogeneity
was high.Table 4
Estimates of association between other noninfectious donor characteristics and RBC transfusio
Outcome or subgroup Studies
Donor cancer
Recipient cancer 1
Previous alloexposure
Mortality 1
TRALI 2
TRALI risk after policy change 2
Walking donors vs random donors
CMV infection 1
HBV infection 1
Parental donors vs unrelated donors
Transfusion reaction
Maternal 1
Paternal 1
Parental 1
Change in hematocrit
Maternal 1
Paternal 1
Abnormal creatinine
Maternal 1
Paternal 1
Parental 1
Abnormal bilirubin 1
Maternal donors vs paternal donors
Transfusion reaction 1
Change in hematocrit 1
Abnormal creatinine 1
Abnormal bilirubin 1Other Noninfectious Donor Characteristics
An additional 4 noninfectious donor characteristics were identiﬁed
(Table 4).
RBC Only. One study published in 1976 with 123 patients assessed
cytomegalovirus (CMV) and hepatitis B virus (HBV) infection risks in pe-
diatric recipients of RBCs from “walking donors” vs “usual” donor and
found no association (OR 1.67 [0.18, 15.02] for CMV, not estimable for
HBV) [54]. One RCT in 40 neonates found no association betweenmater-
nal donors, paternal donors, or unrelated donors and the risk of transfu-
sion reaction, change in hematocrit, and abnormal posttransfusion
creatinine and bilirubin level [55]. Both studies were at high risk of bias.n outcomes
Effect estimate (with 95% CI) Interpretation
RR 1.00 [0.94, 1.06] Null
OR 1.48 [0.48, 4.51] Null, favors alloexposure
OR 0.86 [0.59, 1.27], I2 0% Null, favors no alloexposure
OR 0.78 [0.45, 1.35], I2 0% Null, favors after policy change
OR 1.67 [0.18, 15.02] Null, favors no walking donor
Not estimable Not estimable
Not estimable Not estimable
OR 3.62 [0.14, 95.78] Null, favors random donor
OR 2.33 [0.09, 60.85] Null, favors random donor
MD 0.0 [−3.45, 3.45] Null
MD−0.20 [−3.36, 2.96] Null
OR 0.65 [0.02, 17.65] Null, favors parental donor
OR 1.14 [0.07, 20.02] Null, favors random donor
OR 0.73 [0.04, 12.52] Null, favors random donor
Not estimable Not estimable
OR 0.57 (0.02, 15.58] Null, favors maternal donor
MD 0.20 [−3.37, 3.77] Null
OR 0.57 [0.02, 15.58] Null, favors maternal donor
Not estimable Not estimable
Table 5
Estimates of association between infectious donor characteristics and RBC transfusion outcomes
Outcome or subgroup Studies Effect estimate (with 95% CI) Interpretation
Babesiosis screening
Babesiosis infection 2 RR 0.16 [0.02, 1.31], I2 0% Null, favors after screening
CMV-positive donors
Seroconversion to CMV
Screened vs not screened 2 OR 1.13 [0.86, 1.48], I2 85% Null, favors screened
High titer vs low titer 1 OR 7.04 [1.44, 34.49] Favors low titer
HBV-positive donors
Anti-HBc seroconversion 1 OR 0.33 [0.09, 1.27] Null, favors anti-HBs positive
Any hepatitis 1 OR 0.61 [0.32, 1.17] Null, favors screening
Non-A non-B hepatitis 1 OR 0.17 [0.01, 3.21] Null, favors anti-HBc positive
HCV-positive donors
HCV infection (before and after policy change) 3 OR 0.12 [0.02, 0.84], I2 91% Favors after policy change
HCV infection (positive vs negative blood) 2 OR 0.65 [0.44, 0.95], I2 0% Favors negative donor
HHV8 positive donors
HHV8 seroconversion 1 OR 0.52 [0.27, 0.98] Favors HHB8-negative donor
HTLV-positive donors
HTLV seroconversion 4 OR 54.87 [11.49, 262.01], I2 75% Favors HTLV-negative donor
Parvovirus B19–positive donors
Seroconversion
DNA positive 1 OR 0.03 [0.00, 0.58] Favors low donor viral load
IgM positive 1 OR 0.53 [0.04, 6.51] Null, favors low donor viral load
IgG positive 1 OR 0.04 [0.00, 0.34] Favors low donor viral load
Donor abnormal liver function test
Posttransfusion hepatitis 1 OR 1.63 [0.85, 3.12] Null, favors normal donor liver function test result
Post/transfusion HCV infection 1 OR 3.39 [0.93, 12.35] Null, favors normal donor liver function test result
76 M. Chassé et al. / Transfusion Medicine Reviews 30 (2016) 69–80RBC and Other Blood Components. Four studies reported previous
alloexposures (transfusion or pregnancy) as the exposure of interest,
with no regard to the antibody status, and found no association with
mortality or TRALI [5,15,56,57]. One large population study of good
methodological quality and at low risk of bias found no association be-
tween donor cancer and the risk of cancer in transfusion recipients
(RR 1.00 [0.94, 1.06]) [16]. The proportion of RBC transfusions was not
reported, but the authors performed statistical adjustments by blood
products showing no association with the type of product transfused.
Infectious Donor Characteristics
We identiﬁed 18 studies reporting infectious donor characteristics
(Table 5). The studied pathogens were babesiosis (n = 2) [58,59],
CMV (n = 3) [54,60,61], HBV (n = 3) [62–64], hepatitis C (n =
5) [64–68], human herpesvirus (HHV)8 (n = 1) [69], HTLV (n =
4) [21,70–72], and parvovirus B19 (n = 1) [73]. The included studies
were in general at high risk of bias, used various designs, and had im-
precise estimates. A total of 3 studies included patients that received
RBC transfusions only (babesiosis n = 1, CMV n = 1, parvovirus B19 n
= 1). Donor infectious testing was associated with a statistically signif-
icant reduced infection risk for HCV (OR 0.12 [0.02, 0.84], I2 91% for pol-
icy change) [64,65,68], HHV8 (OR 0.52 [0.27, 0.98]) [69], HTLV (OR 0.02
[0.00, 0.09], I2 75%) [21,70–72], and parvovirus B19 (OR 0.03 [0.00, 0.58]
for DNA positive) [73] but nonsigniﬁcantly reduced risk for babesiosis
(RR 0.16 [0.02, 1.31], I2 0%) [58,59] and HBV (OR 0.61 [0.32, 1.17]) [64].
Subgroup or Sensitivity Analysis
Given the low number of eligible studies for each donor characteris-
tics and outcome, no meaningful prespeciﬁed subgroup or sensitivity
analysis stated in our protocol could be performed.
Risk of Bias
The overall risk of bias and study-speciﬁc risk of bias analyses are
reported in Figure 2 and Appendix 5. Overall, the quality of reporting
was variable. Eighty percent of studies clearly described objectives,
exposures, outcomes, and study population, but less than 50% clearly
described the distribution of confounders, measures of random variabil-
ity, lost to follow-up, and measure of probability values. More than 50%of studies presented at least 1 serious risk of bias, especially concerning
blinding of the subjects or outcome assessments, as well as the selection
of the appropriate analysis for different lengths of follow-up. The risk of
confounding was high in general, as more than 65% of studies did not
appropriately consider confounding or losses of patients to follow-up.
Five studies were randomized, but we were unable to determine if allo-
cation concealmentwas appropriate. Given the low number of included
studies for each donor characteristics and outcome, no funnel plots
were produced to appropriately estimate the risk of publication bias.
Quality of Evidence
We applied the GRADE methodology to assess the quality of the
evidence obtained from this review (Appendix 4). It was estimated to
be very low for all outcomes except for donor cancer and risk of cancer
in the recipient (low), the risk of alloimmunization after transfusion of
HLA-DR selected RBCs in renal transplant recipients (low), and the
change in hematocrit after transfusion of maternal vs paternal RBCs or
random vs parental RBCs (low).
Discussion
In our systematic review, we identiﬁed 17 unique donor characteris-
tics and their potential impact on RBC transfusion recipient outcomes
from59 studies. The quality of the evidence regarding the association be-
tween noninfectious donor characteristics and recipient outcomes was
low to very low, suggesting that any estimate of effect is either uncertain
or that additional research will likely have an important impact and af-
fect our estimates [14]. Because the common design choicewas observa-
tional (and retrospective), the risk of bias and confounding was high.
A very lownumber of studies reported donor age as a potential effect
modiﬁer of outcome in RBC transfusion recipients and was a stated
outcome in only 1 small study [15]. No study reported any evidence of
association between donor age and transfusion outcome. Frompersonal
communications with the authors of 1 study, we found that the maxi-
mum donor age was lower in patients who died in hospital vs patients
who survived [15]. This analysis was performed on the subset of
patients who received RBC transfusions, but all patients also received
plasma. All studies were small and at high risk of confounding, and no
conclusion can be drawn from the gathered evidence.
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Fig 2. Risk of bias.
77M. Chassé et al. / Transfusion Medicine Reviews 30 (2016) 69–80Whether the risk of TRALI is increased after RBC transfusion from fe-
male donors is unclear. From this review, we found very low quality ev-
idence suggesting that a policy change limiting female plasmadonors or
plasma donors positive for antileukocytes antibodies reduces the risk of
RBC-related TRALI. Such ﬁndings are surprising because female donors
were not restricted in any included studies for RBC transfusions. Given
the study design of those studies (before-and-after), theﬁndings are po-
tentially confounded by transfusion of other plasma-rich products to
the recipients. This hypothesis is supported by a null association be-
tween female or mixed RBC donors and the risk of TRALI from an anal-
ysis including 4 observational studies (OR 1.03 [0.64, 1.68]), although
most patients in those studies were also co-transfused with plasma-rich products. The association between female donors and TRALI has
been associated with alloimmunization and the presence of WBC anti-
bodies. When studying speciﬁcally the presence of WBC antibodies in
the blood donor, ourmeta-analysis of 4 studies suggested that the pres-
ence of antibodies in the donor was associated with an increased risk of
TRALI in RBC transfusion recipients (OR 5.84 [1.66, 20.59]). However,
any result from such analyses should be hypothesis generating only,
as the obtained estimate is likely unreliable because of poor study
design and high risk of bias.
One study suggested that donor sex may be associated with survival
when donor sex and recipient sex were mismatched. In this study by
Middelburg and colleagues, the subgroup younger than 55 years that
78 M. Chassé et al. / Transfusion Medicine Reviews 30 (2016) 69–80received only female donor RBCs transfused in male recipients had a
signiﬁcantly decreased survival at 6 months (HR 2.40 [1.10, 5.24]).
This associationwas also seenwhennot restricting to only RBC transfusions
(HR 3.1 [1.5, 6.3]) [31]. If veriﬁed, themechanism of such an association re-
mains tobeexplainedandwill need further study.One could argue that this
sex mismatch association may be due again to the presence of WBC anti-
bodies. However, given the lack of association in female recipients who re-
ceived blood from female donors and a trend for a decreased survival in
femaleswho receive blood frommales, the presence of antibodies is unlike-
ly to be the only explanation. One group proposed that microchimerism
may be present in donor-recipient mismatch transfusion, but this was not
observed in their study [47].
Other antibodies or antigens have been studied in RBC transfusions
and assessed recipients’ clinical outcomes. Compatibility of the
pretransplantation histocompatibility complex (HLA-DR) has been
studied in 8 studies in kidney transplantation and 1 in cardiac trans-
plantation.We found noassociationwith survival. However, transfusion
of HLA-DRmatched bloodwas reported to be associatedwith a reduced
rate of graft rejection and alloimmunization. Such interventions are no
longer used clinically to prevent graft rejection. It however supports
that donormismatchmay affect recipient outcomeby altering the recip-
ient’s immune response. In the general population, similar observations
were obtained from 3 studies studying RBC antigen compatibility and
the risk of clinical alloimmunization. Although routine testing for
blood compatibility is performed before transfusion, for time and
availability considerations, patients often receive unmatched blood for
minor and sometimes major RBC antigens. This associated increased
risk of alloimmunization is however of uncertain long-term clinical
signiﬁcance, and robust evaluations are still needed.
Three additional noninfectious characteristicswere evaluated for their
effect on RBC transfusion outcomes. One large binational study analyzed
the association between diagnosis of cancer after blood donation and
the risk of cancer in the transfusion recipient and showed no association.
The estimate was not provided for RBC transfused patients only, but the
authors reported a multivariable analysis by blood product that did not
modify the risk estimate. This unique study provides weak evidence
that precancerous patients may not increase the risk of cancer in the re-
cipient. In pediatric populations, one study reported no difference in risk
of transmission of CMVwhen using randomdonors or donors speciﬁcally
asked to provide blood for pediatric care (“walking donors”). Another
study comparing blood donated by themother, the father, or randomdo-
nors also showed no difference in clinical outcome. Given the observa-
tional methods used and the small sample size of those 2 last
characteristics, whether such characteristics can affect transfusion out-
come remains unclear.
Transfusion has long been a recognized risk of transmission for cer-
tain infections such as hepatitis and HIV. In our review, we identiﬁed
studies that assessed the risk of transfusion-transmitted diseases. Our
inclusion criteria required that we canmeasure a clinical outcome asso-
ciated with RBC transfusions and that an effect estimate can be mea-
sured (rather than estimated); as such, several studies were excluded
from this review (Appendix 2). It is therefore impossible to use the
observed estimates to compare the risks of transmission of blood-
transmissible pathogens with other blood products or with the overall
risk of transmission when using whole blood. We however found 18
studies that reported a direct measure of association between donor in-
fectious and transfusion outcome. As expected, despite the low number
of studies meeting our inclusion criteria, we found a signiﬁcant associa-
tion between a positive infectious status for CMV (low viral titer), hep-
atitis C, HHV8, HTLV, and parvovirus B19. For hepatitis B and babesiosis,
the included studies did not reach statistical signiﬁcance, although the
trend for infectious transmission was toward a protective effect of neg-
ative donors. No studies looking at HIV-positive donors and RBC trans-
fusion met our inclusion criteria. It may seem at ﬁrst surprising to ﬁnd
so few studies that assessed directly the risk of transmissible pathogens.
Many studies published in the ﬁeld tested for the infectious status of thedonor, excluded such donors from the transfusion pool, and performed
probabilistic estimations of the risk of having an infected unit in the
released units for transfusion. Many more studies did not report the
risk of transmission for RBC units, but only for the global transfused
population, or for whole blood transfusion, rendering estimation of
risk for RBC impossible.
We believe that our rigorousmethodology allowed us to provide the
most extensive systematic review of donor characteristics that may
affect RBC transfusion outcome.We feel conﬁdent that our comprehen-
sive search strategy, detailed risk of bias assessment, and reviewmeth-
odology allowed us to provide a comprehensive and complete review of
the evidence regarding the associations of interest. The quality of the ev-
idence gathered by this review is limited by thequality and design of the
included studies. The pooled estimates provided are highly hypothesis
generating in nature given thehigh statistical and clinical heterogeneity,
the different study designs, and the high risk of bias and confounding of
most included studies. Moreover, a signiﬁcant number of studies were
excluded because itwas impossible to extract estimates for RBC transfu-
sions. This affects mainly the effect estimates for infectious characteris-
tics, as only 3 studies were excluded for the donor sex characteristic. In
addition, we excluded only 5 studies that looked at noninfectious donor
characteristics (prison donors [n = 1], drug users [n = 1], parental do-
nors [n=1], and paid donors [n=2]), all observational in design. Those
exclusions are very unlikely to inﬂuence the conclusions of our study for
noninfectious donor characteristics.
Conclusions
In summary, based on very low to low-quality evidence, some donor
characteristics may affect RBC transfusion outcome. Female donor sex,
positive white blood cells antibodies, HLA-DR antigen selection, and
donor RBC antigen selection may be associated with RBC transfusion
outcomes. However, the designs and methodologies are at a high risk
of bias and confounding, and the number of studies that support these
ﬁndings is limited. The chosen clinical outcomes of interest are most
commonly TRALI and change in infectious status, with survival out-
comes rarely reported. Importantly, the evidence is insufﬁcient to
draw deﬁnitive conclusions for any donor characteristics. Given the po-
tential outcome beneﬁts or risks observed in some studies, further well-
designed studies are needed to better evaluate if an improved selection
of donors by their characteristics (age, sex, etc) improves RBC transfu-
sion outcome. In the age of “big data,” there are tremendous opportuni-
ties for establishing large vein-to-vein data infrastructure that allows for
robust evaluations of the clinical impact of donor characteristics.
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